AFATINIB-RELATED ORAL ULCERATION

Abstract

Treatment of malignant neoplasms with antibodies is associated with oral mucosal side-effects. Afitinib may cause mucocutaneous lesions that mimic ordinary oral ulceration due to the blockage of the epidermal growth factor. This report aimed to describe a case of mucocutanous lesions associated with Afatinib. A 63-year-old Caucasian female, diagnosed with non-small cell lung carcinoma, presented painful, recurrent oral ulcerations since starting treatment for her lung disease. Upon intraoral examination, irregular 3 to 6-mm ulcers surrounded by an erythematous halo were detected in her lower labial mucosa, hard palate, and lingual frenulum. Upon extra-oral examination, ulcerative lesions were also detected on both the right and left aspects of her hallux (big toe) nail. The patient was treated with low-level laser therapy with marked clinical and symptomatic improvement. Treatment of malignant neoplasms with antibodies is associated with oral mucosal side-effects. Afitinib may cause mucocutaneous lesions that mimic ordinary oral ulceration due to the blockage of the epidermal growth factor. This report aimed to describe a case of mucocutanous lesions associated with Afatinib. A 63-year-old Caucasian female, diagnosed with non-small cell lung carcinoma, presented painful, recurrent oral ulcerations since starting treatment for her lung disease. Upon intraoral examination, irregular 3 to 6-mm ulcers surrounded by an erythematous halo were detected in her lower labial mucosa, hard palate, and lingual frenulum. Upon extra-oral examination, ulcerative lesions were also detected on both the right and left aspects of her hallux (big toe) nail. The patient was treated with low-level laser therapy with marked clinical and symptomatic improvement.